Title Page:

2	Metabolic dysfunction-associated steatohepatitis is associated with increased all-
3	cause mortality
4	
5	Running title: MASH can increase the risk of all-cause mortality
6	
7	Zhao Li ^{1#} , Rui Song ^{2#} , Yingzhi Zhang ^{2#} , Jiahe Tan ³ , Zhiwei Chen ^{2*}
8	
9	¹ Department of Gastroenterology, the Seventh People's Hospital of Chongqing,
10	Chongqing, China.
11	² Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of
12	Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the
13	Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
14	³ Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical
15	University, Chongqing, China.
16	
17	# These authors contribute equally to this work.
18	* Corresponding author. Address: Institute for Viral Hepatitis, The Key Laboratory of
19	Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The
20	Second Affiliated Hospital of Chongqing Medical University, 74 Linjiang Road,
21	Yuzhong District, Chongqing 400010, China. E-mail addresses:

²² zhiwei_chen@cqmu.edu.cn. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24

Author's email address:

25	Zhao Li: 1546866602@qq.com
26	Rui Song: sr202099@163.com
27	Yingzhi Zhang: zhangyingzhi217@163.com
28	Jiahe Tan: tanjiahe1995@163.com
29	Zhiwei Chen: zhiwei_chen@cqmu.edu.cn
30	
31	Data Availability Statement: All the data in this study were available in the
32	NHANES III public database.
33	
34	Funding: This work was supported by Remarkable Innovation-Clinical Research
35	Project, The Second Affiliated Hospital of Chongqing Medical University, and The
36	First batch of key Disciplines on Public Health in Chongqing, Health Commission of
37	Chongqing, China.
38	
39	Conflict of interest statement: The authors declare no conflicts of interest.
40	
41	Ethics approval statement and patient consent statement: NHANES III was
42	approved by the CDC/NCHS Ethics Review Board, and all individuals signed
43	informed consent to participate in NHANES III.
44	

45	Permission to reproduce material from other sources: Yes.
46	
47	Clinical trial registration: Not applicable.
48	
49	Word count: 4026.
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	

67 Abstract

68	Background: Recently, the new nomenclature metabolic dysfunction-associated
69	steatohepatitis (MASH) was proposed to supersede non-alcoholic steatohepatitis
70	(NASH). To optimize the management of these patients, it is crucial to comprehend
71	the similarities and differences between individuals with NASH and MASH.
72	Methods: We analyzed data from 13,846 participants in the third National Health and
73	Nutrition Examination Surveys, along with their linked mortality through 2019.
74	NASH and MASH were defined based on respective criteria. Survey-weight adjusted
75	multivariable Cox proportional model was used to examine mortality.
76	Results: The overall prevalence of steatohepatitis, NASH and MASH was 5.7%
77	(n=788), 4.1% (n=564) and 5.5% (n=763), respectively. Most individuals with NASH
78	(96.8%) could be categorized as MASH, but only 69.7% individuals with MASH
79	qualified as NASH. During a median follow-up of 27 years, individuals with MASH
80	exhibited a 53% higher risk of all-cause mortality (adjusted hazard ratio [aHR] 1.53,
81	95% CI 1.24-1.89). But individuals with NASH didn't show an association with all-
82	cause mortality after adjustment for metabolic risk factors (aHR 1.14, 95% CI 0.91-
83	1.44). Notably, individuals who met the criteria for MASH but not NASH
84	(NASH(-)/MASH(+)) had a higher risk of all-cause mortality (aHR 2.47, 95% CI
85	1.71-3.57) compared to those with NASH(+)/MASH(+) (aHR 1.22, 95% CI 0.97-
86	1.55). Moreover, advanced fibrosis was only associated with an increased risk of all-
87	cause mortality in individuals with MASH, not NASH.
88	Conclusions: MASH, rather than NASH, was associated with an elevated risk of all-

89	cause mortality after adjusting for metabolic risk factors.	Well-designed prospective
90	studies are needed to assess and validate our findings.	

91

92	Key words:	NASH; MASH;	mortality; NHANES I	II.
9Z	Key worus:	NASH, MASH,	, monancy, infiances i	l

94	Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,			
95	body mass index; CI, confidential intervals; FIB-4, fibrosis-4; HR, hazard ratio; HEI,			
96	healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis;			
97	MASLD, metabolic dysfunction associated steatotic liver disease; NAFLD,			
98	nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NHANES III,			
99	Third National Health and Nutrition Examination Survey; NFS, NAFLD fibrosis score;			
100	PIR, poverty impact ratio.			
101				
102				
103				
104				
105				
106				
107				
108				
109				
110				

111 Introduction

The most severe form of nonalcoholic fatty liver disease (NAFLD), non-alcoholic 112 steatohepatitis (NASH), significantly heightens the risk of developing cirrhosis and 113 liver cancer¹. Although the prevalence of NASH is relatively low compared to NAFLD, 114 it is witnessing a global upsurge². Recently, the nomenclature for NAFLD has been 115 updated to metabolic dysfunction associated steatotic liver disease (MASLD)³, with 116 NASH now designated as metabolic dysfunction-associated steatohepatitis (MASH). 117 However, whether MASH exhibits similar characteristics or clinical outcomes as 118 119 NASH remains ambiguous. Consequently, it is imperative to address these questions to optimize management strategies for individuals with MASH. 120 Compared with NAFLD, MASLD places greater emphasis on the influence of 121 122 metabolic factors (meeting at least one of the five cardio-metabolic adult criteria, without the constraints of alcohol consumption or viral hepatitis)³. Our previous study, 123 as well as those of others, have demonstrated a high concurrence between NAFLD and 124 MASLD⁴⁻⁸. Nevertheless, the similarities and differences between NASH and MASH 125 remain obscure. As per the definition³, it is speculated that individuals who met NASH 126 definition but not MASH might lack or exhibit mild metabolic risk factors, whereas, 127 those with MASH but not NASH are likely to present with more metabolic risk factors, 128 heavier alcohol consumption, or coexistence of viral hepatitis (hepatitis B or hepatitis 129 C). Although the incidence of discordant subgroups that fulfill the criteria for one but 130 not the other between NASH and MASH might be rare⁹, concrete data is currently 131

132 lacking.

133	A previous investigation utilizing the data from the Third National Health and Nutrition
134	Examination Survey (NHANES III) reported that NASH was not associated with an
135	elevated mortality rate over a 15-year follow-up period ¹⁰ . However, the potential impact
136	of extending the follow-up duration on the outcomes remains undefined. Moreover, it
137	is unclear whether MASH or the discordant subgroups exhibit differing risks of all-
138	cause and cause-specific mortality compared to NASH, necessitating further
139	exploration.

In this study, we employed data from NHANES III, with a 27-year follow-up period, to
compare the similarities and differences in clinical features and long-term mortality
between individuals with non-alcoholic steatohepatitis and metabolic dysfunctionassociated steatohepatitis.

144

145 **Participants and Methods**


146 **Study participants**

In this study, we utilized data from the NHANES III (1988-1994), a comprehensive, 147 stratified, clustered, multi-staged probability sampling design national survey that 148 accurately represents the entire US population¹¹. The outcomes of interviews, physical 149 examinations, and laboratory tests on participants with available liver ultrasonography 150 data were collected and analyzed. This mainly encompassed demographic indices (e.g., 151 sex, age, race, education, smoking or drinking status, concomitant disease etc.), 152 153 anthropometric indices (e.g., body mass index (BMI), waist circumference, etc.), and laboratory tests (e.g., alanine aminotransferase (ALT), aspartate aminotransferase 154

(AST), and triglyceride, etc.). The NHANES mortality follow-up was a prospective
study that dynamically assessed the vital status of all participants (≥20 years). Causespecific and all-cause mortality data were obtained from the National Death Index up
to December 2019¹². Detailed information on data collection and mortality evaluation
is provided in the supplementary materials. All individuals participating in NHANES
III signed informed consent.

161 Definition of NASH, MASH, and Fibrosis

As liver biopsies were not obtained in NHANES III, steatohepatitis was defined as mild 162 163 to severe hepatic steatosis with elevated liver enzymes levels based on a previous study¹⁰. NASH was defined as the presence of steatohepatitis in the absence of 164 excessive alcohol consumption (≥ 20 g/d for females and ≥ 30 g/d for males) and/or other 165 liver diseases (such as viral hepatitis)¹⁰. MASH was defined by the presence of 166 steatohepatitis in conjunction with at least one of the five cardio-metabolic adult 167 criteria³. The detailed cardio-metabolic criteria are provided in the supplementary 168 169 materials. We further categorized concordant NASH(+)/MASH(+) individuals as those who met both NASH and MASH definitions, while NASH(-)/MASH(-) individuals 170 satisfied neither NASH nor MASH criteria. For the discordant subgroups, individuals 171 fulfilling the NASH definition but not MASH were labeled as NASH(+)/MASH(-), and 172 vice versa for those meeting MASH but not NASH, who were defined as 173 NASH(-)/MASH(+). Finally, individuals without hepatic steatosis were designated as 174 175 the control group.



employed various non-invasive fibrosis scores as alternatives. The NAFLD fibrosis
score (NFS) and fibrosis-4 (FIB-4) score were selected based on prior studies^{13,14},
which can be further categorized into low, intermediate, and high probabilities for
advanced fibrosis. We defined advanced fibrosis as individuals presenting at least one
of the two scores indicating a high probability of advanced fibrosis.

182 Statistical analysis

The data are presented as median and interguartile range (IQR) for continuous variables, 183 unweighted frequency counts and weighted percentage for categorical variables. The 184 185 Wilcoxon test was employed for continuous variables, while the chi-square test was utilized for categorical variables. Cox proportional hazards regression was employed to 186 estimate hazard ratios (HR) and 95% confidence intervals (CI) for deaths from all-187 188 causes and cause-specific (cardiovascular disease and cancer). We utilized two models with progressive degrees of adjustment: model 1 adjusted for demographic indices (sex, 189 age, race, marital status, education, poverty impact ratio (PIR), healthy eating index 190 191 (HEI) scores, sedentary lifestyle, and smoking status), while model 2 further adjusted for metabolic risk factors (BMI, waist circumference, triglycerides, and high-density 192 lipoprotein cholesterol). For sensitivity analysis, firstly, to assess the impact of hepatic 193 steatosis severity, we excluded individuals with mild hepatic steatosis from those with 194 195 hepatic steatosis. Secondly, to avoid the potential confounding effect of viral hepatitis, we excluded participants with hepatitis B or hepatitis C from the entire population. All 196 197 analyses were conducted using R (version 4.3.0; R Foundation for Statistical Computing, Vienna, Austria), with the survey package employed to account for the 198

sampling weights and the complex survey design in the NHANES III.

200

201 **Results**

202 Characteristics of individuals with NASH or MASH

Of the 14,797 participants (20-74 years) who underwent hepatic/gallbladder ultrasound 203 examinations in the NHANES III, 941 individuals were excluded due to ungradable or 204 missing ultrasound images. In addition, 10 participants without follow-up data on 205 mortality were also excluded. Consequently, 13,846 participants from NHANES III 206 207 were included in this study (Table S1). The overall prevalence of steatohepatitis, NASH, and MASH were 5.7% (n=788), 4.1% (n=564), and 5.5% (n=763), respectively. To 208 focus on steatohepatitis more effectively, individuals with hepatic steatosis and normal 209 210 liver enzyme levels (n=4,225) were further excluded from the entire population. Ultimately, a total of 9,621 individuals were included for subsequent analyses. 211 Compared to individuals without hepatic steatosis, those with steatohepatitis were more 212 213 likely to be older, male, non-Hispanic black, less educated, poorer, have increased liver 214 enzyme levels, and exhibit metabolic abnormalities (Table 1).

Of note, a significant majority individuals with NASH (96.8%) can be classified as MASH, yet only 69.7% of those with MASH can be qualified as NASH. Specifically, of the 788 individuals diagnosed with steatohepatitis, 69.3% of the subjects were assigned to the NASH(+)/MASH(+) subgroup, followed by NASH(-)/MASH(+), NASH(+)/MASH(-), and NASH(-)/MASH(-) subgroups (27.5%, 2.3%, and 0.9%, respectively; Figure 1). Notably, the subgroups characterized by MASH(+) exhibited

elevated coexisting metabolic risk factors, while those characterized by NASH(-)
demonstrated higher alcohol consumption and proportion of viral hepatitis, particularly
in the NASH(-)/MASH(+) subgroup (Table S2).

224 All-cause and cause-specific mortality of individuals with NASH or MASH

During the median follow-up period of 27.0 years (23.3-29.0), the cumulative mortality 225 rate from all-cause was 32.3% (3,105 deaths). Cause-specific mortality was attributed 226 to cardiovascular disease and cancer, accounting for 8.5% (816 deaths) and 8.1% (777 227 deaths), respectively. As shown in Table 2, individuals with NASH exhibited a 1.3-fold 228 229 increased risk of all-cause mortality compared to those without NASH (HR 1.29, 95% CI 1.01-1.65). After adjusting for demographic and traditional risk factors, the 230 association between NASH and all-cause mortality remained significant (Model 1: 231 232 adjusted HR [aHR] 1.41, 95% CI 1.14-1.74). However, this association was attenuated when further adjusting for metabolic risk factors (Model 2: aHR 1.14, 95% CI 0.91-233 1.42). Notably, individuals with MASH exhibited higher all-cause mortality rate than 234 235 those without MASH in both models (Model 1: aHR 1.74, 95% CI 1.44-2.1; Model 2: aHR 1.53, 95% CI 1.24-1.89). Intriguingly, subgroup analysis revealed that only the 236 NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups demonstrated significantly 237 elevated all-cause mortality rates compared to individuals without hepatic steatosis in 238 239 model 2 (aHR 2.47, 95% CI 1.71-3.57; aHR 3.65, 95% CI 1.48-9.04). The concordant NASH(+)/MASH(+) subgroup showed no association with all-cause mortality after 240 241 further adjusting for metabolic risk factors (aHR 1.22, 95% CI 0.97-1.55). (Table 2) Regarding cause-specific mortality, neither NASH nor MASH, nor their combined 242

subgroups demonstrated an association with cardiovascular mortality (Model 2: aHR

244 0.74-1.43) or cancer mortality (Model 2: aHR 1.25-1.87; Table 3).

245 The effect of fibrosis on all-cause mortality in individuals with NASH or MASH

Given that individuals with NASH have a higher propensity to develop fibrosis than 246 those with NAFLD¹⁵, we ponder whether such fibrosis augments the risk of all-cause 247 mortality in NASH or MASH patients. Interestingly, advanced fibrosis was merely 248 associated with an elevated risk of all-cause mortality in individuals with MASH, but 249 not NASH (Model 2: aHR 1.7, 95% CI 1.12-2.58, p=0.012; aHR 1.39, 95% CI 0.86-250 251 2.22, p=0.2; Table 4). In particular, both the NFS and FIB-4 scores demonstrated a graded increase in the risk of all-cause mortality in individuals with MASH. That is, 252 compared to the low probability subgroup, the high probability of advanced fibrosis 253 254 subgroup exhibited a higher risk of mortality than the intermediate probability subgroup

- 255 (NFS score: aHR 2.05, 95% CI 1.1-3.83; aHR 3.23, 95% CI 1.32-7.88; FIB-4 score:
- aHR 1.42, 95% CI 0.87-2.32; aHR 2.62, 95% CI 1.26-5.41). A similar trend was also

observed in the NFS score of individuals with NASH (aHR 2.12, 95% CI 1.06-4.25;

aHR 2.32, 95% CI 1.02-5.3), whereas, no such discrepancy was detected in the FIB-4

score. (Table 4)

257

260 Sensitivity analyses for individuals with NASH or MASH

First, we wonder whether the hepatic steatosis degrees could affect the clinical outcomes. After excluded individuals with mild hepatic steatosis from those with hepatic steatosis, similar findings of mortality outcomes were observed (Table S3-5). Second, to avoid the potential confounding effect of viral hepatitis, we excluded

individuals with hepatitis B or hepatitis C from the whole population. In this scenario, 265 the increased all-cause mortality was also observed in individuals with MASH, and 266 267 NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups (Table S6). For the causespecific mortality, the cardiovascular and cancer mortality were also not associated with 268 both NASH or MASH and their combinations (Table S7). Even though the high NFS 269 and FIB-4 scores subgroups still showed higher risk of all-cause mortality among 270 individuals with MASH, the difference was not significant in increased all-cause 271 mortality in MASH individuals with advanced fibrosis, after excluded participants with 272 273 viral hepatitis (Model 2: aHR 1.41, 95% CI 0.99-2.03, p=0.059; Table S8). Firstly, we examined the potential impact of hepatic steatosis severity on clinical 274 275 outcomes. By excluding individuals with mild hepatic steatosis from those with hepatic 276 steatosis, we observed similar mortality outcomes (Table S3-5). Secondly, to mitigate the potential confounding influence of viral hepatitis, we excluded individuals with 277 hepatitis B or hepatitis C from the study population. In this context, increased all-cause 278 279 mortality was also noted in individuals with MASH, as well as in the NASH(-)/MASH(+) and NASH(-)/MASH(-) subgroups (Table S6). Regarding cause-280 specific mortality, cardiovascular and cancer mortality were not associated with both 281 NASH and MASH, nor with their combinations (Table S7). Although individuals with 282 283 MASH in the high NFS and FIB-4 score subgroups exhibit a higher risk of all-cause mortality, the increased risk of all-cause mortality among MASH patients with 284 285 advanced fibrosis does not reach statistical significance, after excluding participants with viral hepatitis (Model 2: aHR 1.41, 95% CI 0.99-2.03, p=0.059; Table S8). 286

287

288 Discussion

289 The recent proposal of the new nomenclature MASH to replace NASH necessitates a thorough understanding of the similarities and differences between individuals with 290 NASH and MASH, in order to optimize the management of these patients. In this study, 291 although patients with NASH exhibited similar clinical features regarding metabolic 292 risk factors compared to those with MASH, it was found that MASH, not NASH, was 293 significantly associated with an increased all-cause mortality after adjusting for 294 295 metabolic risk factors. Additionally, advanced fibrosis in patients with MASH was associated with a higher risk of all-cause mortality compared to those with NASH. 296 These findings imply that independent of metabolic risk factors, there exists a strong 297 298 correlation between MASH and an increase in all-cause mortality.

NASH can contribute to progressive fibrosis, and in some cases, cirrhosis or even liver 299 cancer¹. However, a previous study found no correlation between NASH and an 300 increase in all-cause mortality following a 15-year follow-up in NHANES III¹⁰. Using 301 a longer follow-up period (27 years), we reiterated that NASH per se is not associated 302 with all-cause mortality after adjusting for metabolic risk factors. Notably, in contrast 303 to the previous study¹⁰, NASH increases the risk of all-cause mortality when only 304 adjusting for demographic and traditional risk factors (model 1), but not metabolic risk 305 factors. Although the definition of NASH does not encompass metabolic risk, 306 307 individuals with NASH exhibit similar metabolic characteristics to those with MASH in this study. Consequently, caution should be exercised for the long-term prognosis of 308

individuals with NASH, particularly those with a high risk of concurrent conditions
(e.g., type 2 diabetes mellitus¹⁶ or liver cirrhosis¹⁷). Nevertheless, individuals with
MASH exhibit a 53% higher risk of all-cause mortality than those without MASH even
after adjusting for metabolic risks. This suggests that MASH can identify individuals
with a higher risk of all-cause mortality than NASH. Therefore, greater attention and
early intervention are warranted for those with MASH, such as lifestyle
modification^{18,19}, or other novel therapies^{20,21}.

When we further categorized individuals with steatohepatitis into four subgroups, 316 317 interesting findings regarding all-cause mortality emerged. In Model 1, individuals with NASH(+)/MASH(+) exhibited a 47% increased risk of all-cause mortality, which 318 disappeared after further adjusting for metabolic risk factors. This suggests that 319 320 metabolic factors play a significant role in the elevation of all-cause mortality risk for these individuals. Notably, individuals with NASH(-)/MASH(+) still exhibited a 2.47-321 fold risk of all-cause mortality even after adjusting for metabolic risk factors. This 322 indicates that, beyond metabolic factors, heavy alcohol consumption and/or viral 323 hepatitis may have a more potent impact on the risk of all-cause mortality for MASH 324 patients^{22,23}. After excluding individuals with viral hepatitis in the sensitivity analysis, 325 the high all-cause mortality risk persisted. This suggests that significant alcohol 326 consumption, rather than viral hepatitis, could be responsible for the increased all-cause 327 mortality risk. However, this should be interpreted with caution due to the small sample 328 size. Larger studies are needed to verify these findings in the future. A similar 329 phenomenon was also observed in individuals with NASH(-)/MASH(-), although the 330

sample size was smaller. This subgroup represents a relatively small proportion of individuals with concurrent liver disease but without metabolic comorbidities. After excluding individuals with viral hepatitis, this discordant group may be attributed to alcoholic steatohepatitis (ASH), which could contribute to the interpretation of the increased risk of all-cause mortality²⁴. Therefore, based on these observations, it is crucial to distinguish between MASH with concurrent liver disease and its absence in future studies.

In this study, a significant majority of patients with NASH (96.8%) are classified as 338 339 MASH, with only 3.2% lacking metabolic risk factors. This finding is consistent with a previous review⁹, and supports the retention and validity of historical data from 340 NASH clinical trials. However, the situation becomes distinct when reversed. As it is 341 342 not a prerequisite to exclude concurrent liver diseases for the diagnosis of MASH, MASH may encompass a broader range of individuals with various liver disease 343 etiologies (viral, alcoholic, autoimmune, genetic, etc.), akin to MASLD³. Specifically, 344 only 69.7% of individuals with MASH can be confirmed as having NASH, suggesting 345 that 30.3% of these individuals harbor alternative etiologies (excessive alcohol 346 consumption and/or viral hepatitis) in this analysis. The gap may vary with differing 347 population selection. Moreover, in this context, it appears challenging to differentiate 348 between MASH and hepatitis induced by other etiologies (e.g., ASH or active viral 349 hepatitis). This could potentially impact the risk of all-cause mortality for these patients 350 351 directly, as mentioned above. From this aspect, it may be advantageous to appropriately refine or qualify the new term of MASH in order to mitigate this ambiguity. 352

To our knowledge, no study has previously evaluated the association between MASH 353 and mortality. This is the strength of our study. However, there are several limitations 354 355 to our study. First, although this is a nationally representative study based on the NHANES III dataset (1988-1994), the low prevalence of steatohepatitis at that time 356 resulted in a relatively small sample of patients with NASH or MASH. Large-sample 357 studies focusing on these patients are needed to validate our observations. Second, 358 steatohepatitis was not confirmed by liver biopsy but by ultrasound examination, which 359 may underestimate the prevalence and impact on clinical outcomes of individuals with 360 NASH or MASH²⁵. However, the advantages of ultrasound, such as safety, affordability, 361 sufficient sensitivity, and satisfactory specificity, make it suitable for use in large 362 population-based epidemiologic studies²⁶. Third, in the US population-based study, the 363 364 prevalence of viral hepatitis (especially hepatitis B) was low, therefore, the results in this regard should be interpreted with caution. Further studies are needed to clarify the 365 specific effect of viral hepatitis on the mortality of individuals with MASH, especially 366 in high-prevalence areas of viral hepatitis, such as Asia and Africa²⁷. 367

In summary, our research demonstrates for the first time a significant association between MASH and increased all-cause mortality, independently of metabolic and demographic risk factors. In contrast, NASH exhibits a heightened risk of all-cause mortality, while it becomes non-significant following adjustment for metabolic risk factors. Moreover, it is crucial to differentiate between individuals with concomitant liver disease and those without when studying MASH. In future, well-designed prospective studies with large sample sizes are needed to assess and validate our

375 findings.

377	Acknowledgement: We gratefully acknowledge the contribution of the participants of
378	the NHANES cohort, research assistants, and facilitating personnel. And this work was
379	supported by the Science and technology research project of Chongqing Education
380	Commission (KJZD-K202300404), Remarkable Innovation-Clinical Research Project
381	and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical
382	University, and The First batch of key Disciplines on Public Health in Chongqing,
383	Health Commission of Chongqing, China.
384	
385	
386	Conflict of interest statement: The authors declare no conflicts of interest.
387	
388	Ethics approval statement
389	The National Center for Health Statistics Research Ethics Review Board approved the
390	NHANES protocol.
391	
392	Data Availability Statement
393	All data produced in the present study are available upon reasonable request to the
394	authors.
395	
396	Author contributions: Rui Song, Zhao Li and Yingzhi Zhang was involved in
	18

397	acquis	sition of data, data analysis and interpretation, drafting of the manuscript, and	
398	study supervision. Jiahe Tan were involved in interpretation of data and critical		
399	revision of the manuscript. Zhiwei Chen was involved in study concept and design,		
400	interp	retation of data, drafting of the manuscript, critical revision of the manuscript,	
401	and st	udy supervision. All authors contributed to the article and approved the	
402	submi	tted version.	
403			
404	Refer	ence	
405	1.	Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related	
406		HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol	
407		Hepatol. 2021;18(4):223-238.	
408	2.	Brennan PN, Elsharkawy AM, Kendall TJ, Loomba R, Mann DA, Fallowfield	
409		JA. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-	
410		centric approach. Nat Rev Gastroenterol Hepatol. 2023;20(10):679-688.	
411	3.	Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus	
412		statement on new fatty liver disease nomenclature. J Hepatol. 2023.	
413	4.	Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and	
414		MASLD characteristics and mortality outcomes in United States adults. Liver	
415		Int. 2024;44(4):1051-1060.	
416	5.	Perazzo H, Pacheco AG, Griep RH. Changing from NAFLD through MAFLD	
417		to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. J	
418		Hepatol. 2024;80(2):e72-e74.	

419	6.	Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet
420		MASLD criteria and natural history is therefore identical. J Hepatol.
421		2024;80(2):e76-e77.
422	7.	Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data
423		under the new MASLD definition? J Hepatol. 2024;80(2):e54-e56.
424	8.	Ratziu V, Boursier J. Confirmatory biomarker diagnostic studies are not needed
425		when transitioning from NAFLD to MASLD. J Hepatol. 2024;80(2):e51-e52.
426	9.	Yeh ML, Yu ML. From nonalcoholic steatohepatitis, metabolic dysfunction-
427		associated fatty liver disease, to steatotic liver disease: Updates of nomenclature
428		and impact on clinical trials. Clin Mol Hepatol. 2023;29(4):969-972.
429	10.	Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and
430		mortality among US adults: prospective cohort study. Bmj. 2011;343:d6891.
431	11.	CfDCaP NCfHS. Analytic and reporting guidelines: The Third National Health
432		and Nutrition Examination Survey, NHANES III (1988-94). 1996;
433		https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-
434		reporting-guidelines.pdf (Access on 2024.04.01).
435	12.	Statistics NCfH. 2019 Public-Use Linked Mortality Files. 2022;
436		https://www.cdc.gov/nchs/data-linkage/mortality-public.htm (Access on
437		2024.04.01).
438	13	Angulo P Hui IM Marchesini G et al The NAFLD fibrosis score: a

Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a 438 13. noninvasive system that identifies liver fibrosis in patients with NAFLD. 439 Hepatology. 2007;45(4):846-854. 440


- 14. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison
- 442 of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver
- disease. *Clin Gastroenterol Hepatol.* 2009;7(10):1104-1112.
- Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. *Nat Rev Gastroenterol Hepatol.* 2023;20(10):633-646.
- 16. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty
- liver disease in type 2 diabetes mellitus: an updated systematic review and meta-
- 448 analysis. *Gut.* 2023;72(11):2138-2148.
- Lim WH, Ng CH, Tan D, et al. Natural history of NASH cirrhosis in liver
 transplant waitlist registrants. *J Hepatol.* 2023;79(4):1015-1024.
- 451 18. EASL-EASD-EASO Clinical Practice Guidelines for the management of non452 alcoholic fatty liver disease. *J Hepatol.* 2016;64(6):1388-1402.
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of
 nonalcoholic fatty liver disease: Practice guidance from the American
 Association for the Study of Liver Diseases. *Hepatology*. 2018;67(1):328-357.
- 456 20. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of
- 457 Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *N Engl J Med.*
- 458 2021;384(12):1113-1124.
- 459 21. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in
 460 Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002.
- 461 22. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. *Nat Rev Dis*462 *Primers*. 2018;4(1):16.


463	23.	You H, Wang F, Li T, et al. Guidelines for the Prevention and Treatment of
464		Chronic Hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425-
465		1442.
466	24.	Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH.
467		Dig Dis. 2011;29(2):202-210.
468	25.	Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease.
469		Gastroenterology. 2002;123(5):1705-1725.
470	26.	Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging
471		in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-750.
472	27.	Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global
473		burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516-537.
474		
475		
476		
477		
478		
479		
480		
481		
482		
483		
484		



487

488 Figure and figure legend





497

499

	No hepatic steatosis	Steatohepatitis	Р	NASH	MASH	
Characteristics	(n=8,833)	(n=788)		(n=564)	(n =763)	
Age (years)	38.0 (28.0, 51.0)	40.0 (33.0, 53.0)	0.003	40.0 (32.0, 52.0)	41.0 (33.0, 53.0)	
Sex (male)	4,027 (47%)	445 (58%)	0.007	290 (55%)	429 (58%)	
Race			< 0.001			
Non-Hispanic white	3,293 (76%)	186 (66%)		138 (70%)	181 (67%)	
Non-Hispanic black	2,829 (12%)	149 (8.6%)		318 (14%)	410 (14%)	
Mexican-American	2,324 (4.8%)	421 (13%)		89 (6.6%)	141 (8.4%)	
Others	387 (7.7%)	32 (12%)		19 (9.8%)	31 (11%)	
Body mass index (kg/m ²)	24.7 (22.1, 27.6)	30.0 (26.6, 35.1)	< 0.001	30.6 (27.0, 35.6)	30.3 (27.1, 35.2)	
Waist circumference (cm)	88 (79, 96)	104 (94, 112)	< 0.001	105 (94, 112)	104 (94, 112)	
≥12 years education	5,716 (79%)	389 (70%)	< 0.001	284 (74%)	373 (69%)	
Marital status	5,445 (66%)	493 (63%)	0.3	374 (66%)	484 (63%)	
PIR	2.9 (1.7, 4.3)	2.3 (1.1, 3.8)	0.016	2.4 (1.2, 3.9)	2.2 (1.1, 3.9)	
HEI score	63 (54, 73)	61 (53, 73)	0.4	63 (53, 74)	61 (53, 72)	
Hypertension	2,458 (23%)	334 (49%)	< 0.001	237 (47%)	334 (51%)	
Diabetes	581 (3.9%)	170 (20%)	< 0.001	134 (21%)	170 (21%)	
Smoking status			0.004			
Never	4,341 (46%)	377 (45%)		310 (50%)	363 (44%)	
Past smoker	1,824 (22%)	195 (30%)		148 (33%)	191 (31%)	
Current smoker	2,668 (32%)	216 (24%)		106 (17%)	209 (25%)	
Alcohol consumption (g/d)	4 (1, 12)	8 (2, 28)	0.003	3 (0, 10)	8 (2, 28)	
Viral hepatitis (HBV/HCV)	242 (2.2%)	96 (10%)	< 0.001	0	96 (11%)	
Sedentary lifestyle	2,420 (19%)	261 (23%)	0.2	199 (24%)	256 (23%)	

Table 1. Baseline characteristics of individuals with NASH or MASH.

Triglycerides (mg/dL)	1.1 (0.8, 1.6)	1.9 (1.2, 3.2)	< 0.001	2.1 (1.4, 3.6)	2.0 (1.3, 3.3)
HDL-cholesterol (mg/dL)	1.3 (1.1, 1.6)	1.1 (0.9, 1.4)	< 0.001	1.0 (0.9, 1.3)	1.1 (0.9, 1.4)
Glucose (mol/L)	5.1 (4.8, 5.4)	5.4 (5.1, 6.2)	< 0.001	5.4 (5.0, 6.1)	5.5 (5.1, 6.2)
ALT (U/L)	13 (10, 18)	47 (37, 63)	< 0.001	47 (37, 63)	47 (36, 63)
AST (U/L)	18 (16, 22)	39 (33, 53)	< 0.001	38 (31, 48)	39 (32, 53)

Data are shown as the median (interquartile range) or unweighted frequency counts (weighted percentage) as appropriate. The Wilcoxon test for continuous variables and the Chi-square test for categorical variables were used in this analysis.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

	Ν	n	Univariable model		Multivariable Model 1		Multivariable Model 2	
		(deaths)	HR (95% CI)	Р	HR (95% CI)	Р	HR (95% CI)	Р
No NASH	9057	2900	1		1		1	
NASH	564	205	1.29 (1.01-1.65)	0.042	1.41 (1.14-1.74)	0.001	1.14 (0.91-1.44)	0.2
No MASH	8858	2792	1		1		1	
MASH	763	313	1.8 (1.45-2.23)	< 0.001	1.74 (1.44-2.1)	< 0.001	1.53 (1.24-1.89)	< 0.001
No hepatic steatosis	8833	2785	1		1		1	
NASH(+)/MASH(+)	546	203	1.41 (1.08-1.82)	0.01	1.47 (1.18-1.82)	< 0.001	1.22 (0.97-1.55)	0.1
NASH(+)/MASH(-)	18	2	0.11 (0.02-0.61)	0.012	0.41 (0.07-2.44)	0.3	0.29 (0.03-2.77)	0.3
NASH(-)/MASH(+)	217	110	3.12 (2.39-4.06)	< 0.001	2.51 (1.77-3.56)	< 0.001	2.47 (1.71-3.57)	< 0.001
NASH(-)/MASH(-)	7	5	4.02 (1.56-10.4)	0.004	3.01 (1.27-7.16)	0.012	3.65 (1.48-9.04)	0.005

Table 2. Association among NASH or MASH status and all-cause mortality.

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1.

BMI, body mass index; CI, confidential intervals; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

	Ν	n	Univariable model		Multivariable Model 1		Multivariable Model 2	
		(deaths)	HR (95% CI)	Р	HR (95% CI)	Р	HR (95% CI)	Р
Cardiovascular mortality	,							
No NASH	9057	778	1		1		1	
NASH	564	38	1.03 (0.68-1.57)	0.9	1.14 (0.78-1.67)	0.5	0.74 (0.48-1.13)	0.2
No MASH	8858	763	1		1		1	
MASH	763	53	1.29 (0.9-1.87)	0.2	1.25 (0.87-1.78)	0.2	0.87 (0.58-1.32)	0.5
No hepatic steatosis	8833	762	1		1		1	
NASH(+)/MASH(+)	546	38	1.11 (0.73-1.69)	0.6	1.17 (0.8-1.7)	0.4	0.76 (0.5-1.15)	0.2
NASH(+)/MASH(-)	18	0	/	/	/	/	/	/
NASH(-)/MASH(+)	217	15	1.88 (0.92-3.85)	0.085	1.48 (0.57-3.82)	0.4	1.43 (0.53-3.87)	0.5
NASH(-)/MASH(-)	7	1	0.34 (0.04-3.13)	0.3	0.27 (0.03-2.88)	0.3	0.87 (0.08-9.15)	>0.9
Cancer mortality								
No NASH	9057	732	1		1		1	
NASH	564	45	1.04 (0.63-1.71)	0.9	1.25 (0.74-2.11)	0.4	1.25 (0.73-2.14)	0.4
No MASH	8858	704	1		1		1	
MASH	763	73	1.42 (0.97-2.07)	0.073	1.43 (0.94-2.19)	0.1	1.48 (0.91-2.4)	0.11
No hepatic steatosis	8833	704	1		1		1	
NASH(+)/MASH(+)	546	45	1.13 (0.68-1.86)	0.6	1.29 (0.76-2.19)	0.3	1.32 (0.76-2.27)	0.3
NASH(+)/MASH(-)	18	0	/	/	/	/	/	/
NASH(-)/MASH(+)	217	28	2.35 (1.33-4.13)	0.003	1.78 (0.97-3.24)	0.062	1.87 (0.97-3.59)	0.06
NASH(-)/MASH(-)	7	0	/	/	/	/	/	/

Table 3. Association among NASH or MASH status and cardiovascular disease and cancer-related mortality.

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1. BMI, body mass index; CI, confidential intervals; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; PIR, poverty impact ratio.

	N	n	Univariable model		Multivariable Model 1		Multivariable Model 2	
	Ν	(deaths)	HR (95% CI)	Р	HR (95% CI)	Р	HR (95% CI)	Р
NASH								
No advanced fibrosis	503	161	1		1		1	
Advanced fibrosis	55	43	4.39 (2.68-7.19)	< 0.001	1.51 (0.92-2.47)	0.1	1.39 (0.86-2.22)	0.2
Low NFS	377	78	1		1		1	
Intermediate NFS	141	93	4.85 (2.60-9.03)	< 0.001	2.65 (1.41-4.99)	0.002	2.12 (1.06-4.25)	0.033
High NFS	40	33	7.69 (3.55-16.7)	< 0.001	3.11 (1.62-5.97)	< 0.001	2.32 (1.02-5.30)	0.046
Low FIB-4	394	92	1		1		1	
Intermediate FIB-4	123	79	3.88 (2.31-6.52)	< 0.001	1.45 (0.81-2.61)	0.2	1.35 (0.66-2.73)	0.4
High FIB-4	41	33	8.87 (5.36-14.7)	< 0.001	1.62 (0.75-3.50)	0.2	1.95 (0.94-4.06)	0.074
MASH								
No advanced fibrosis	665	236	1		1		1	
Advanced fibrosis	91	75	4.37 (3.18-6.01)	< 0.001	1.92 (1.27-2.91)	0.002	1.70 (1.12-2.58)	0.012
Low NFS	499	123	1		1		1	
Intermediate NFS	199	139	3.84 (2.38-6.19)	< 0.001	2.55 (1.46-4.45)	< 0.001	2.05 (1.10-3.83)	0.024
High NFS	58	49	7.38 (4.21-12.9)	< 0.001	4.40 (2.21-8.73)	< 0.001	3.23 (1.32-7.88)	0.01
Low FIB-4	501	126	1		1		1	
Intermediate FIB-4	180	121	3.05 (2.12-4.39)	< 0.001	1.38 (0.89-2.14)	0.15	1.42 (0.87-2.32)	0.2
High FIB-4	75	64	8.01 (5.29-12.1)	< 0.001	2.32 (1.26-4.27)	0.007	2.62 (1.26-5.41)	0.01

Table 4. Association of advanced fibrosis status and all-cause mortality among individuals with NASH or MASH.

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, race, marital status, education, PIR, HEI scores, sedentary lifestyle, and smoking status.

Multivariate model 2 was further adjusted for BMI, waist circumference, triglycerides, and high-density lipoprotein cholesterol in addition to model 1.

BMI, body mass index; CI, confidential intervals; FIB-4, fibrosis-4; HR, hazard ratio; HEI, healthy eating index; MASH, metabolic dysfunction-associated steatohepatitis; NASH, nonalcoholic steatohepatitis; NFS, NAFLD fibrosis score; PIR, poverty impact ratio.